a public good project by the
Synthesis
Company
of California

© 2026

Peter Bernhardt | doi.page

0 works0 citations0 h-index

Peter Bernhardt

Sahlgrenska University Hospital(SE)Sahlgrenska University Hospital(SE)University of Gothenburg(SE)

Publications by Year

Research Areas

Radiopharmaceutical Chemistry and Applications, Neuroendocrine Tumor Research Advances, Medical Imaging Techniques and Applications, Neuroblastoma Research and Treatments, Lung Cancer Research Studies

Most-Cited Works

→ Specific Growth Rate versus Doubling Time for Quantitative Characterization of Tumor Growth Rate(2007)240 cited
→ Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer(2019)220 cited
→ EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands(2022)218 cited
→ Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice(2014)212 cited
→ Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry(2017)199 cited
→ Exendin-4–Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT(2010)155 cited

→ Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate(2013)

135 cited

→ EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres(2021)123 cited

→ A Transplantable Human Carcinoid as Model for Somatostatin Receptor-Mediated and Amine Transporter-Mediated Radionuclide Uptake(2001)118 cited

→ Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment(2015)109 cited